2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 275

A Comparison of the Clinical Features and Natural History of Autoimmune Interstitial Lung Disease Vs. Idiopathic Pulmonary Fibrosis
Abstract Number: 276

Long-Term Outcome in Mixed Connective Tissue Disease
Abstract Number: 277

Rituximab in Refractory Mixed Connective Tissue Disease: An Observational Study
Abstract Number: 278

Mitral Valve Prolapse in Patients with Joint Hypermobility Syndrome
Abstract Number: 279

Ehlers-Danlos Syndrome Hypermobility Type (Type III) Is Associated with Rheumatological Conditions
Abstract Number: 280

The Fascia Is a Target Organ of Inflammation in Autoimmune Diseases
Abstract Number: 281

Health Related Quality of Life Is Reduced in Adult Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 282

Angiogenesis in Fasciitis Associated with Dermatomyositis
Abstract Number: 283

Altered Serum Fatty Acid Profiles in Patients with Polymyositis or Dermatomyositis Compared to Healthy Individuals and in Relation to Immunosuppressive Treatment
Abstract Number: 284

Validation of the Sporadic Inclusion Body Myositis Physical Functioning Assessment
Abstract Number: 285

Tobacco Smoking in Different Racial Groups Is Differentially Associated with the Development of Myositis Autoantibodies and Interstitial Lung Disease in the Idiopathic Inflammatory Myopathies
Abstract Number: 287

Interleukin-35 in Idiopathic Inflammatory Myopathies
Abstract Number: 288

Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
Abstract Number: 289

Evaluation of Usefulness of Krebs Von Den Lungen-6 As a Biomarker of Interstitial Lung Disease with Polymyositis and Dermatomyositis Including in the Short Time Course after Treatment
Abstract Number: 290

Cancer and Necrotizing Immune Mopathy: High Incidence in Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive and Seronegative Patients but Not in Anti-Single Recognition Particle Positive Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].